

## SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Le, Junming Vilcek, Jan 5 Daddona, Peter E. Ghrayeb, John Knight, David M. Siegel, Scott A. (ii) TITLE OF INVENTION: MONOCLONAL AND CHIMERIC ANTIBODIES 10 SPECIFIC FOR HUMAN TUMOR NECROSIS FACTOR (iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Browdy and Neimark (B) STREET: 419 Seventh Street, N.W. 15 (C) CITY: Washington (D) STATE: D.C. (E) COUNTRY: USA (F) ZIP: 20004 20 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, 25 Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: 30 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/670,827 (B) FILING DATE: 18-MAR-1991 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 202-628-5197 35 (B) TELEFAX: 202-737-3528 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 157 amino acids (B) TYPE: amino acid 40 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val 45 Val Ala Asn Pro Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg

Ala Asn Ala Leu Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu
35 40 45

		Val	Val 50	Pro	Ser	Glu	Gly	Leu 55	Tyr	Leu	Ile	туз	Se1	c Glr	val	l Leu	Phe
		Lys 65	Gly	Gln	Gly	Сув	Pro	Ser	Thr	His	Val	. <b>Le</b> u 75	ı Lev	ı Thi	Hia	5 Thr	11e 80
5		Ser	Arg	Ile	Ala	Val 85	Ser	Туг	Gln	Thr	Lys 90	Va]	. Asr	ı Leı	ı Leı	Ser 95	Ala
		Ile	Lys	Ser	Pro 100		Gln	Arg	g Glu	Thr 105		Glu	ı Gly	/ Ala	Gl: 110	ı Ala	Lys
10		Pro	Trp	Tyr 115		Pro	Ile	туг	120		Gly	v Val	Phe	125		ı Glu	Lys
		Gly	Asp 130	_	Leu	Ser	Ala	Glu 135		Asn	Arg	Pro	140	_	Let	qaA ı	Phe
		Ala 145	Glu	Ser	Gly	Gln	Val 150	_	Phe	Gly	Ile	11e		a Leu	l		
15	(2)	INFO	RMAT	ION	FOR	SEQ	ID N	iO:2:	;								
		(i)	(B	) LE: ) TY: ) ST:	NGTH PE: RAND	: 32 nucl EDNE	1 ba eic SS:	se p ació sing	airs I								-
20		(44)	(D	•	POLO												
		(11)	MOL		B 11	PB:	CDNA	•									
		(ix)		TURE ) NA ) LO	ME/K			21									
25		(xi)	SEQ	UENC	E DE	SCRI	PTIC	N: S	EQ I	D NO	:2:						
		ATC Ile															4.8
30	Glu	AGA Arg	Val	Ser	Phe	Ser	Cys	Arg	Ala	Ser	Gln	Phe	Val		Ser		96
		CAC His															144
35		TAT Tyr 50															192
40		GGA Gly															240
		GAT Asp															288

I:\gkt\app\vilcek3b.ap! September 11, 1992

100

	(2)	INF	ORMA'	TION	FOR	SEQ	ID I	10:3	:								
5			(i) :	(B)	LEI TY		: 10 amin	7 am: cac:	ino a id		3						
		(:	ii) 1	MOLE	CULE	TYPI	E: p:	rote:	in								
10		(:	xi) !	SEQUI	ENCE	DES	CRIP	rion	: SE	O ID	NO:	3:					
	Asp 1	Ile	Leu	Leu	Thr 5	Gln	Ser	Pro	Ala	Ile 10	Leu	Ser	Val	Ser	Pro 15	Gly	
	Glu	Arg	Val	Ser 20	Phe	Ser	Сув	Arg	Ala 25	Ser	Gln	Phe	Val	Gly 30	Ser	Ser	
15	Ile	His	Trp 35	Tyr	Gln	Gln	Arg	Thr 40	Asn	Gly	Ser	Pro	Arg 45	Leu	Leu	Ile	
	Lys	Tyr 50	Ala	Ser	Glu	Ser	Met 55	Ser	Gly	Ile	Pro	Ser 60	Arg	Phe	Ser	Gly	
20	Ser 65	Gly	Ser	Gly	Thr	Asp 70	Phe	Thr	Leu	Ser	Ile 75	Asn	Thr	Val	Glu	Ser 80	
	Glu	Asp	Ile	Ala	Asp 85	Tyr	Tyr	Cys	Gln	Gln 90		His	Ser	Trp	Pro 95	Phe	
	Thr	Phe	Gly	Ser 100	Gly	Thr	Asn	Leu	Glu 105	Val	Lys						
25	(2)	INF	ORMA'	rion	FOR	SEQ	ID 1	NO:4	:								
30		(i)	() () ()	QUENC A) Li 3) TY C) SY O) TC	INGTI (PE : (RANI	nucl	57 ba leic SSS:	ase p acio sino	pair:	5							
		(ii)	MOI	LECUI	LE TY	PE:	CDN	Ŧ									
		(ix)	(2	ATURE A) NZ 3) LC	ME/I			357									
35		(xi)	SEÇ	QUENC	CE DE	SCR	[PTIC	ON: S	SEQ 1	D NO	0:4:						
		GTG Val															48
40		ATG Met															96

ACG TTC GGC TCG GGG ACA AAT TTG GAA GTA AAA Thr Phe Gly Ser Gly Thr Asn Leu Glu Val Lys

321

				TGG Trp													144
5				AGA Arg													192
				GGG Gly													240
10				CAA Gln													288
15				AGG Arg 100													336
				CTC Leu													357
	(2)	INFO	RMA	гіои	FOR	SEQ	ID 1	10:5	:								
20			(i) S	SEQUE							_						
				(B)		PE: a	amino	aci	id	actu	si .						
		<b>(</b> )	ii) M	(B)	TYI	POLOC	amino 3Y: I	o aci linea	id ar	acia	š						
25				(B) (D)	TYI	PE: 8 POLOC	amino BY: I	o aci linea	id ar in			5:					
25	Glu 1	()	ci) S	(B) (D)	TYI TOI CULE	PE: 6 POLOG TYPE DESG	amino SY: 1 S: p:	o aci linea rotei	id ar in : SE(	O ID	NO: 5		Gln	Pro	Gly 15	Gly	
25	1	() Val	ci) S Lys	(B) (D) MOLEC	TYI TOI CULE ENCE Glu 5	PE: 6 POLOC TYPE DESC	amind SY: 1 S: pr CRIPT	o aci linea rotei rion:	id ar in : SE( Gly	O ID Gly 10	NO: 5	Val			15		
<b>25</b> <b>30</b>	1 Ser	(al Val Met	ci) S Lys Lys	(B) (D) MOLEC SEQUE Leu	TYI TOI CULE SNCE Glu 5	PE: 6 POLOG  TYPE  DESG  Glu  Cys	amind GY: ] G: pr CRIPT Ser Val	D acilines rotes FION: Gly Ala	id in : SEG Gly Ser 25	Gly 10 Gly	NO:5	Val Ile	Phe	Ser 30	15 Asn	His	
	1 Ser Trp	Val Met Met	Lys Lys Lys Asn 35	(B) (D) (D) (OLE) SEQUE Leu Leu 20	TYII TOI CULE SNCE Glu 5 Ser Val	PE: 6 POLOG  TYPE  DESG  Glu  Cys  Arg	emind SY: D S: pr CRIPT Ser Val Gln Ser	rotes FION: Gly Ala Ser 40	id in : SEG Gly Ser 25 Pro	Gly Gly Gly Glu Ser	NO:S Leu Phe Lys	Val Ile Gly Thr	Phe Leu 45 His	Ser 30 Glu	15 Asn Trp	His Val	
	Ser Trp	Val Met Met Glu 50	Lys Lys Asn 35	(B) (D) (OLEC SEQUE Leu Leu 20 Trp	TYII TOP  CULE SNCE Glu 5 Ser Val	PE: 6 POLOG  TYPE  DESG  Glu  Cys  Arg	Ser  Ser  Ser  Ser  Ser	rotes rotes rotes rION: Gly Ala Ser 40 Ile	id in : SE( Gly Ser 25 Pro	Gly Gly Gly Glu Ser	NO: S Leu Phe Lys Ala	Val Ile Gly Thr 60	Phe Leu 45 His	Ser 30 Glu Tyr	15 Asn Trp Ala	His Val Glu	
30	Ser Trp Ala Ser 65	Val Met Met Glu 50 Val	Lys Lys Asn 35 Ile	(B) (D) (D) (D) (D) (E) (E) (E) (E) (E) (E) (E) (E) (E) (E	TYII TOI CULE SNCE Glu 5 Ser Val Ser	PE: 6 POLOC TYPE DESC Glu Cys Arg Lys Phe 70	Ser Val Ser Ser Thr	Control of the second of the s	id in : SEG Gly Ser 25 Pro Asn Ser	Gly Gly Glu Ser	NO:S Leu Phe Lys Ala Asp	Val Ile Gly Thr 60 Asp	Phe Leu 45 His	Ser 30 Glu Tyr Lys	15 Asn Trp Ala Ser	His Val Glu Ala 80	
30	Ser Trp Ala Ser 65 Val	Val Met Met Glu 50 Val	Lys Lys Asn 35 Ile Lys Lys	(B) (D) (OLEC SEQUE Leu 20 Trp Arg	TYII TOI TOI TOI TOI TOI TOI TOI TOI TOI T	PE: 6 POLOC  TYPE  DESC  Glu  Cys  Arg  Lys  Phe  70	Ser Val Ser 55 Thr	Control of the contro	id in : SEG Gly Ser 25 Pro Asn Ser	Gly Gly Glu Ser Arg Thr 90	NO:S Leu Phe Lys Ala Asp 75	Val Ile Gly Thr 60 Asp	Phe Leu 45 His Ser	Ser 30 Glu Tyr Lys Gly	Asn Trp Ala Ser Val	His Val Glu Ala 80 Tyr	